FORSCEY, PLLC for BARR LABORATORIES
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 14, 2009 | $60,000 | Replaced |
| 4th Quarter - Termination Amendment | Feb 19, 2009 | $60,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Opposition to changes in legal doctrines of inequitable conduct that would make it harder for generic drug firms to pursue invalidity claims; S. 1145 Patent Reform Act of 2007.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A FORSCEY | Managing Partner |
Health Issues HCR
Advance proposal to create an FDA process for the approval of generic biological products; S. 316 - Preserve Access to Affordable Generics Act; H.R. 1902 - Protecting Consumer Access to Generic Drugs Act; H.R. 1038 - Access to Life Saving Medicine Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A FORSCEY | Managing Partner |
| JOHN STINSON | Partner |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.